The pre-clinical efficacy of this agent on chemosensitive HCC in vitro and in vivo models has been already proved [31,57]; finding that regorafenib could even palliate the loss of sorafenib sensitivity mediated by hepatocyte growth factor in the conventional non-resistant HCC cell lines SMMC-7721 and HepG2 [58]. This evidence concerns the gene HGF and hepatocellular carcinoma.